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Legal Disclaimer 
The following presentation is only 
intended to be educational and is not 
intended to provide legal advice.   
 
No attorney-client relationship is being 
established by this presentation. 
 
No client-confidential information is 
being disclosed.  All information is 
publicly available. 
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Consider this… 
• US Blockbuster drugs >$1 billion  
– (Lipitor® ~$11.7 billion 2010) 
 
• $1.3 billion to develop a drug  
 
• 5,000 compounds  5 human testing 
 … only one is approved 
 
• 1-of-every-3 drugs approved 
recuperates development costs  
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Top 10 Rx Drugs in 2014 
Consensus sales forecasts for world's top 10 drugs in 2014 * 
 
1.  Avastin (cancer)  Roche  $8.9 Bil. 
2.  Humira (arthritis)  Abbott  $8.5 Bil. 
3.  Enbrel  (arthritis)   Pfizer/Amgen $8.0 Bil. 
4.  Crestor (cholesterol)   AstraZeneca $7.7 Bil. 
5.  Remicade (arthritis)  Merck/J&J  $7.6 Bil. 
6.  Rituxan (cancer)  Roche  $7.4 Bil. 
7.  Lantus (diabetes)  Sanofi-Aventis  $7.1 Bil. 
8.  Advair (asthma/COPD)     GSK   $6.8 Bil. 
9.  Herceptin (cancer)  Roche  $6.4 Bil. 
10. NovoLog (diabetes)   Novo Nordisk  $5.7 Bil. 
 
*Source : Thompson-Reuters 
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Top 5 U.S. Drug Patent Expirations 
in 2011 
Pfizer (Atorvastatin).  Ranbaxy has a 6 month 
agreement to begin selling generic in Nov., 2011    
  
Eli Lilly & Co. (Olanzapine).  Antipsychotic drug for 
schizophrenia and bipolar disorder.  $1 B sales in 
2010.      
  
J&J (Levofloxacin).  Antibiotic commonly used to 
treat severe to life-threatening bacterial infections. 
$434 M sales in 2010. Hi-Tech Pharmacal obtained 
exclusive generic rights of oral solution for 6 mo. 
   
J&J (Methylphenidate).  Drug for attention-deficit 
disorder.  $ 362 M in sales in 2010.  
  
Pfizer (Pantoprazole).  Popular antacid. 
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Avg. 5-6 years of Patent 
Exclusivity 
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Fernandez, et al., “Strategic Balancing of Patent and FDA Approval Processes to Maximize Market  
Exclusivity”, www.iploft.com, 2011. 
FDA Approval / Patent Exclusivity 
Timeline 
Evergreening  
 
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The Big Pharma Market 
• Unpredictable and 
hazardous … 
• Unexpected side 
effects…  
• New drugs with 
superior efficacy 
marginalize old 
drugs immediately 
and indefinitely. 
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Pharma IP Evergreening 
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Is Pharma IP 
Evergreening Simply 
Monopoly Extension ?  
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Traditional Pharma: “Small Molecules” 
 
Olanzapine 
              1 nm  
 
 
NanoPharma:  Nanoparticles of small 
molecules 
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Many ways to 
make 
medicine 
“nano”… 
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cool pic from nanoparticles.org 
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Nano is Great for 
Patenting ! 
• Unpredictable 
• Unexpected Results 
• New Formulations 
• New Compositions 
• Different/new dosage regimens 
   ... and hopefully safer and more 
effective than traditional pharma 
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Recent Nanomedicine Patents 
US8017156   Long-acting colloidal insulin 
formulation and its preparation FLAMEL TECH 
 
US8003127    Nanoparticulate corticosteroid 
and antihistamine formulations methods of 
making, and methods of administering 
thereof   Elan Pharma International Limited  
 
US7998477 Spherical protein particles and 
methods for making and using them   Althea 
Technologies, Inc. 
 
US7910577  Injectable nanoparticulate 
olanzapine formulations Elan Pharma 
International Limited  
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US8017156 Long-acting colloidal insulin 
formulation and its preparation using at least one 
poly(Leu-block-Glu) in which the pH is between 
5.8 and 7.0  
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Big Pharma’s Nanotech 
Patent Portfolios 
• Elan – 44  “distinct patent families” 
• Roche – 19 
• Novartis – 18 
• Abbott - 14 
• Pfizer – 13 
• Bristol-Meyers Squibb – 10 
• AstraZeneca - 8 
• Sanofi – 3 
• GlaxoSmithKline – 0 
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nano orange book patents ? 
~6600 U.S. Patents listed 
in the FDA’s Orange Book  
~2000 U.S. nanomedicine 
patents 
 
To Date: About 40 
nanotech patents listed 
in the Orange Book  
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nano orange book patents 
nanoparticulate TriCor (fenofibrate)    
U.S. Patents:  
7,875,630            
7,820,788             
7,741,374            
7,741,373             
7,569,612         
7,320,802            
7,276,249                   
7,101,576 
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Top 10 Rx Drugs in 2010 
 Source : Thompson-Reuters 
1. Lipitor (cholesterol)  Pfizer   $11.7 Bil. 
2. Plavix (anticlotting)  Sanofi/BMS   $9.6 Bil. 
3. Advair (asthma/COPD)  GSK   $9.0 Bil. 
4. Remicade (arthritis)  Merck/J&J  $7.4 Bil. 
5. Enbrel (arthritis)   Pfizer/Amgen $7.1 Bil. 
6. Humira (arthritis)  Abbott  $6.8 Bil. 
7. Avastin (cancer)   Roche  $6.7 Bil. 
8. Rituxan (cancer)  Roche  $6.1 Bil. 
9. Diovan (hypertension)  Novartis  $6.0 Bil. 
10.Crestor (cholesterol)  AstraZeneca $5.8 Bil. 
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Nanomedicine Patenting by 
Big Pharma 
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Bristol Myers Squibb 
• 7 Issued U.S. Nanomed Patents, e.g.,  
–7255875, Integrin Targeted 
Imaging Agents (using an emulsion 
of nanoparticles) [Not in Orange 
Book] 
–7115587, Aripiprazole complex 
formulation and method [In Orange 
Book] 
–antipsychotic agent aripiprazole 
in the form of an inclusion 
complex in a β-cyclodextrin  
 
 
©2011 Woodcock Washburn LLP 
Cyclodextrin 
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WO2008079834A2 
 
PREPARATION OF PARAMAGNETIC 
NANOPARTICLES CONJUGATED TO 
LEUKOTRIENE B4 (LTB4) RECEPTOR 
ANTAGONISTS, AND THEIR USE AS MRI 
CONTRAST AGENTS FOR THE DETECTION 
OF INFECTION AND INFLAMMATION 
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Abbott: -Labs, -Cardiovascular, 
 Diabetes Care, -Medical Optics 
14 families of nanomed patents 
4 issued patents, none in Orange Book 
 
• Formulations comprising lipid-regulating agents 
 
• Nanocrystals for use in topical cosmetic 
formulations and method of production thereof 
 
• Nanoparticle-coated medical devices and 
formulations for treating vascular disease 
 
• Therapeutic composition with enhanced 
endothelium targeting nanoshells on polymers 
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US20080255403A1  
Magnetic Nanoparticle Therapies 
Various compositions, methods, and devices are 
provided that use fluorescent nanoparticles, which 
can function as markers, indicators, and light 
sources.  
The fluorescent nanoparticles can be formed from 
a fluorophore core surrounded by a biocompatible 
shell, such as a silica shell.  
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• 20 distinct nanomed patent families 
–Mainly UV protection agents and 
pigments (for sunscreens) 
• 6 issued patents 
• None listed in Orange Book 
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Pfizer’s 5 Issued Nanotech Patents >2001 
US Pat No. 
6852746 
Title 
Crystalline drug form 
Composition / Orange 
Book? 
6-[(2,2-
diphenylethyl)amino…  / No 
6548555 Basic drug compositions 
with enhanced 
bioavailability 
 (general structures) / No 
6713461 Pharmaceutical complex Eletriptan / No 
6632803 Pharmaceutical 
formulations containing 
voriconazole (with 
cyclodextrin, lyophilized) 
Voriconazole (Vfend –
antifungal) / Yes ($1 Bil) Lit! 
6232304 Inclusion complexes of aryl-
heterocyclic salts (with 
cyclodextrin) 
Ziprasidone 
(Geodon/Zeldox -
antipsychotic) / Yes ($1 bil) 
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Nanoformulation “Evergreening” of Drugs 
Coming Off Patent in 2011 
Atorvastatin - 15 new patents (Lipocine, Inc., 
NanoPax Pharma, Orbus Pharma, Flamma, Sp.A); 
nanoparticles and improved delivery   
Olanzapine – 12 new patents (Elan Pharma – orange 
book, Acusphere, Skye Pharma, academia); mainly 
various nanoparticulate formulations    
Levofloxacin – 15 new patents (Acusphere, Sonus 
Pharm., UNC, Revalesio Corp., Pari Pharma); mainly 
various nanoparticulate formulations  
Methylphenidate – 5 new patents (i.e., solid lipid 
nanoparticles)  
 
Pantoprazole – 6 new patents (i.e., cyclodextrin…) 
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Future Nanomedicine IP 
Battlegrounds ? 
• Drug Delivery 
–Site-specific targeted drug-delivery 
systems (dendrimers, nanoshells, 
nanoparticles, nanoliposomes) 
• Personalized Medicine 
–Pharmacogenetics, pharmacogenomics 
• Expiration of Traditional Blockbuster Drug 
Patents improved with nanotech (Product-
Line Extensions, Patent Evergreening) 
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Nanomedicine IP 
 
many nanoparticle patents   
    
 several in the orange book 
 
 big pharma has few nanopharma patents 
 
 evergreening today’s blockbusters with 
nanotech  most likely future IP battles… 
 
 Current Nanomed Patent Litigation: 
 Pfizer v. Vfend  U.S. Pat. No. 6632803  
 Pharmaceutical formulations containing voriconazole 
(with cyclodextrin, lyophilized) 
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Which phrase is more “PC”? 
 
“IP Evergreening”  
 
or  
 
“Next Generation Pharma 
Technology” 
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Thank you. 
Jeffrey H. Rosedale, Ph.D.  
Partner, Woodcock Washburn, LLP 
Philadelphia, Pennsylvania 
jrosedale@woodcock.com 
215-564-8969 
 
